1. Home
  2. SCOR vs AKTX Comparison

SCOR vs AKTX Comparison

Compare SCOR & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

HOLD

Current Price

$6.70

Market Cap

112.4M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$3.53

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCOR
AKTX
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
6.5M
IPO Year
2007
2014

Fundamental Metrics

Financial Performance
Metric
SCOR
AKTX
Price
$6.70
$3.53
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
10.9K
25.1K
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
127.37
N/A
EPS
4.25
N/A
Revenue
$403,549,000.00
N/A
Revenue This Year
$2.75
N/A
Revenue Next Year
$7.30
N/A
P/E Ratio
$1.65
N/A
Revenue Growth
1.02
N/A
52 Week Low
$4.39
$0.12
52 Week High
$10.18
$6.59

Technical Indicators

Market Signals
Indicator
SCOR
AKTX
Relative Strength Index (RSI) 37.93 42.12
Support Level $6.28 $0.36
Resistance Level $7.07 $6.53
Average True Range (ATR) 0.43 0.78
MACD -0.09 -0.44
Stochastic Oscillator 8.08 16.22

Price Performance

Historical Comparison
SCOR
AKTX

About SCOR comScore Inc.

comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: